Boehringer Ingelheim buys oncology biotech for up to $1.3B
Boehringer Ingelheim is paying up to $1.3 billion to acquire a relatively unknown immuno-oncology biotech out of La Jolla, CA.
The German drug giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
